ABT-737 Enhances Paclitaxel Treatment for Hepatoblastoma
Author Information
Author(s): Lieber Justus, Eicher Carmen, Wenz Julia, Kirchner Bettina, Warmann Steven W, Fuchs Jörg, Armeanu-Ebinger Sorin
Primary Institution: Department of Paediatric Surgery and Paediatric Urology, University Children's Hospital, Tübingen, Germany
Hypothesis
Can the BH3 mimetic ABT-737 improve the effectiveness of paclitaxel in treating hepatoblastoma?
Conclusion
The combination of ABT-737 and paclitaxel significantly reduces tumor volume in hepatoblastoma models compared to paclitaxel alone.
Supporting Evidence
- ABT-737 reduced viability in hepatoblastoma cell cultures at concentrations above 1 μM.
- Combination treatment allowed for a tenfold reduction in paclitaxel dosage while maintaining efficacy.
- Significantly lower relative tumor volumes were observed in the combination treatment group compared to controls.
Takeaway
Using ABT-737 with paclitaxel helps shrink liver tumors in kids with a type of liver cancer called hepatoblastoma.
Methodology
The study involved treating hepatoblastoma cell lines and xenografts with paclitaxel, ABT-737, and their combination, followed by viability assays and tumor volume measurements.
Potential Biases
There may be bias in the selection of treatment dosages and the animal model used.
Limitations
The study was limited by the small sample size and the potential for toxicity in the combination treatment.
Participant Demographics
The study used NOD/LtSz-scid IL2Rγnull mice for xenotransplantation.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website